Seattle genetics laid its foundation in the year 1998 and has its headquarters in Bothell, Washington. The company completed its first public offering in the year 2011 and is also a member of the NASDAQ. Till date, this company has over 550 employees and all are driven with passion for helping people who are suffering from cancer. They also strive hard and leave no stone unturned in reaching out to the masses where medical facilities are few and limited.
Popular biotech products
Seattle genetics developed ADCETRIS (brentuximab vedotin) which is meant for intravenous use only. This medication is meant for patients with relapsed Hodgkin lymphoma and systematic anaplastic large cell lymphoma. This drug received approval from FDA in the year 2011 and is the first in new class of ADCs (antibody - drug conjugates).
ADCETRIS contains anti-CD30 monoclonal antibody that has cell – killing agent like properties – properties that have been developed by Seattle genetics ADC technology. This drug has participated in more than 20 ongoing clinical trials and 4 phase III studies. The trials are designed to test the efficacy of this drug in treating the early signs of lymphoma as well as certain additional types of CD-30 positive malignancies that includes cutaneous T-cell lymphoma (CTCL), B-cell lymphomas and mature T-cell lymphomas (MTCL).
ADCEETRIS is approved in over 30 countries for treatment of relapsed Hodgkin lymphoma. These countries include United States, Canada, European Union and Switzerland. It is this one drug belonging to the class of ADCs that has been in use for more than 30 years in the United States for treating Hodgkin Lymphoma. Seattle genetics has joined hands with Millennium for jointly developing ADCETRIS.
Almost all the latest discoveries of Seattle genetics belong to the class of ADCs and are targeted towards treating several types of cancers. All the drugs have passed the phase I of clinical trials and the company will soon begin their testing of phase II followed by phase III after which they will be sent to FDA for approval. The following is a list of latest discoveries by Seattle genetics:
• SGN – 75 for treating Renal cell carcinoma and everolimus.
• ASG – 22ME targeted towards treating solid tumors.
• SGN – CD19A meant for treating acute lymphoblastic leukemia and non – Hodgkin lymphoma.
• SGN – CD33A developed for treating acute myeloid leukemia.
• ASG – 15ME for treating bladder cancer.
• SGN – LIV1A developed for treating breast cancer.
All these are antibody – drug conjugates and are designed to specifically target the cancer cells while leaving the healthy cells untouched.
Recent company takeovers
Seattle genetics is expanding its business by collaborating with various firms for the ADC technology. The collaborating firms include AbbVie, Agensys, Bayer, Celldex, Daiichi Sankyo, Genentech, GlaxoSmithkline, Millennium, Pfizer and Progenics. Seattle genetics may also join hands with Genmab for expanding its area of research for the ADC class of drugs.
Recent corporate news
Seattle genetics is symbolized as SGEN in the NASDAQ stock. The price of stock of this firm is about $41.08.
In the year 2012, the European Commission, granted conditional marketing authorization for ADCETRIS to Millennium. Health Canada also approved the drug but with conditions in the year 2013.
Seattle genetics have benefitted a lot from the various collaborations for the ADC technology. Till date the firm has generated more than $225 million from the multiple licensing agreements and is expected to get an additional amount of $3.5 billion as potential milestones and royalties. In addition to this, there are more than 10 collaborator ADC programs in clinical development.
Seattle genetics believes in making a positive impact in the lives of people struggling to outlive cancer. Individuals working with this firm are energetic, vibrant and can go to any extent to develop excellent ADC drugs for beating cancer to life. The employees of Seattle genetics work in collaboration to understand the values and goals of the organization and transform the ideas into targeted action. The firm appreciates and recognizes hard work and rewards its employees. It provides compensation and also has a benefit package that covers stock options, dental, medical, and disability insurance. The firm also has employee stock purchase plan and a 401 (K) plan for its employees. Seattle genetics rewards its employees for bringing laurels to the company by developing breakthrough technology for treating and beating a disease like cancer.
Any event in Seattle genetics is interesting with the regular innovations and developments they are coming up towards the treatment of cancer. The year 2013 has indeed been an eventful year for this firm. This year has witnessed the initiation of several clinical trials for some of the company’s new drugs.
Several drugs developed by this firm have entered into the second phase of clinical trials but are yet to receive approval from the FDA. Seattle genetics in collaboration with millennium has entered into the Phase III clinical trial for ADCETRIS CD-30. This drug is formulated for its action against mature T-cell lymphoma.
In the same year, the firm announced the initiation of two phases I trials for SGN-CD19A. The reports of all the trials are simultaneously presented in conferences to keep the world informed about the research data. The company also presented its reports on the second quarter of 2013 financial results.
Recent job openings
Seattle genetics is forever on the hunt for dynamic and highly qualified individuals to join their firm. The firm provides its employees with the appropriate resources to succeed and excel in their respective fields. Individuals who wish to build their future and career at Seattle genetics can drop in their resume and go through the recruitment process. The firm also has a reserved place for individuals with disabilities and they too can get in touch with the human resources department for the recruitment process.